Valuation : Seres Therapeutics, Inc.

Market Cap 49.21M 42.24M 39.55M 36.21M 68.22M 4.7B 68.41M 468M 183M 2.37B 185M 181M 7.84B P/E 2026 *
-1.41x
P/E 2027 * -1x
Enterprise Value 49.21M 42.24M 39.55M 36.21M 68.22M 4.7B 68.41M 468M 183M 2.37B 185M 181M 7.84B EV / Sales 2026 *
3.57x
EV / Sales 2027 * 180x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Seres Therapeutics, Inc.

1 day+3.99%
1 week+8.32%
Current month+2.48%
1 month+2.06%
3 months-35.12%
6 months-43.36%
Current year-66.73%
1 week 4.44
Extreme 4.4356
5.15
1 month 4.32
Extreme 4.315
5.65
Current year 4.32
Extreme 4.315
16.42
1 year 4.32
Extreme 4.315
29.98
3 years 4.32
Extreme 4.315
73.4
5 years 4.32
Extreme 4.315
233.8
10 years 4.32
Extreme 4.315
770
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2026
Chief Executive Officer 58 31/07/2025
President 51 01/03/2026
Director TitleAgeSince
Chairman 70 01/03/2026
Director/Board Member 50 14/01/2019
Director/Board Member 80 31/03/2015
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Sell

General Counsel

-82 0.0008%
17/08/26 Sell

Director

-263 0.0027%
17/08/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
+3.99%+8.32%-73.78%-92.99% 49.21M
+3.31%-3.70%+61.03%+103.64% 70.64B
+0.02%+0.62%+50.61%+93.27% 66.11B
-1.03%+0.46%+8.14%-5.28% 27.98B
-2.41%-2.95%-9.77%+455.82% 26.51B
+0.30%-0.69%+63.18%+11.93% 26.44B
+1.02%+6.43%+269.42%+420.34% 20.4B
+0.72%+1.44%+35.32%-17.03% 20.17B
-1.91%-4.37%+13.33%+531.29% 15.99B
-1.50%+2.92%+43.50%+151.30% 13.69B
Average +0.25%+1.72%+46.10%+165.23% 28.8B
Weighted average by Cap. +0.47%+0.65%+56.64%+154.65%

Financials

2026 *2027 *
Net sales 13.8M 11.84M 11.09M 10.15M 19.13M 1.32B 19.18M 131M 51.33M 664M 51.8M 50.68M 2.2B 274K 235K 220K 201K 379K 26.12M 380K 2.6M 1.02M 13.16M 1.03M 1M 43.57M
Net income -37.49M -32.18M -30.13M -27.59M -51.97M -3.58B -52.12M -357M -139M -1.8B -141M -138M -5.97B -78.95M -67.77M -63.45M -58.1M -109M -7.54B -110M -751M -294M -3.8B -296M -290M -12.58B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
27/08/26 US$4.950 +3.99% 22,869
26/08/26 US$4.760 -4.80% 58,204
25/08/26 US$5.000 +7.30% 102,958
24/08/26 US$4.660 +2.19% 74,812
21/08/26 US$4.560 -0.22% 45,418
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.950USD
Average target price
17.00USD
Spread / Average Target
+243.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock